Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study

Exclusion Criteria

• •Anticoagulant therapy prior to trial entry for \> 96 hours
• •Severe thrombocytopenia (platelets \<50·109/L)
• •Severe renal failure - creatinine clearance \<30 ml/min
• •The patients will be treated with catheter based thrombolysis for deep venous thrombosis or systemic thrombolysis for severe pulmonary embolism
• •Pregnancy or breastfeeding.
• •Childbearing potential without proper contraceptive measures
• •Drug abuse or mental disease that may interfere with treatment and follow-up.
• •Severe malabsorption so that oral treatment are expected to have reduced effect
• •Mechanical heart valves
• •Known allergy to apixaban
• •Active bleeding or severe risk of bleeding so that the risk of bleeding is considered a greater danger than the risk of not treating the venous thrombosis
• •Clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis, or cirrhosis)
• •Concomitant use of strong cytochrome P-450 3A4 inhibitors (e.g., human immunodeficiency virus protease inhibitors or systemic ketoconazole, voriconazole or posaconazole) or inducers (e.g., rifampicin, carbamazepine, or phenytoin). Fluconazol is allowed.